
Zumutor: A leading Immuno-Oncology firm innovating NK cell therapies and novel immunotherapies.
Zumutor Biologics, founded in 2015, is a pioneering Immuno-Oncology company specializing in targeted NK cell therapeutics. With a mission to innovate and develop novel immunotherapies, Zumutor leverages two proprietary Antibody Engineering Platforms to enhance innate immunity and regulate the tumor microenvironment. Their flagship platform, INABLR™, generates first-in-class therapeutic antibodies aimed at combating cancer. The company operates from its headquarters at CIC Cambridge Campus in Cambridge, MA, USA, and maintains an ISO-certified laboratory in Bangalore, India.
Notable figures associated with Zumutor include its CEO and founder, Kavitha Iyer Rodrigues. The company has attracted significant investment from prominent venture capital firms such as Bharat Innovation Fund and Accel Partners. Key achievements include the development of multiple first-in-class therapeutic antibodies and securing several patents for their proprietary technologies. Zumutor's impact is evident in its contributions to advancing cancer treatment through innovative NK cell therapies, positioning it as a leader in the Immuno-Oncology space.

Meditope Biosciences
meditope.com

INmune Bio
inmunebio.com

Zebra Biologics

Inceptor Bio
inceptor.bio

Torl Biotherapeutics
torlbio.com

Catamaran Bio
catamaranbio.com

Numab
numab.com

MonarchBio
monarch-bio.com

LTZ Therapeutics

BioLoomics
bioloomics.com

Immpact Bio
immpact-bio.com

Bolt Biotherapeutics
boltbio.com

Targazyme
targazyme.com

Abintus Bio
abintusbio.com

Nantkwest
Companies similar to Zumutor Biologics include Meditope Biosciences, INmune Bio, Zebra Biologics and Inceptor Bio.
Zumutor Biologics was founded in 2015.
Zumutor Biologics' headquarters is located in Bangalore, Karnataka, IN.
Zumutor Biologics' most recent funding round was for $6.2M (USD) in December 2021.
As of Dec 9, 2021, Zumutor Biologics has raised a total of $41.7M (USD).
Zumutor Biologics has 29 employees as of Feb 4, 2024.